Ocugen, Inc.

Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Show More...

  • Website http://www.ocugen.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 0.84 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -79.65 -263.4 -410.99 -145.2 -130.8 -59.4 -47.4 -1.46 5.67
    Dividends USD
    Payout Ratio % *
    Shares Mil 1.0 14.0 27.0
    Book Value Per Share * USD 18.95 163.52 11.72 -11.75 -9.36 -0.25 0.1
    Free Cash Flow Per Share * USD -94.19 -143.49 -123.32 -70.34 -32.5 -3.28
    Return on Assets % -80.47 -143.48 -26.18 -62.62 -38.05 -95.51 -59.88 -118.26 -108.96
    Financial Leverage (Average) 1.21 1.3 2.66 1.53 1.69
    Return on Equity % -77.72 -66.39 -383.37
    Return on Invested Capital % -74.91 -63.2 -276.26 -536.57
    Interest Coverage -10.45
    Current Ratio 3.42 2.03 7.13 4.91 6.2 2.15 5.71 3.47 3.43
    Quick Ratio 3.34 1.72 7.04 4.86 6.17 2.1 5.41 1.64 0.96
    Debt/Equity 0.02 0.02 0.010 0.11 0.23